The Senate Health, Education, Labor and Pensions Committee advanced President Donald Trump’s nominees to lead the Centers for Disease Control and Prevention and the federal office responsible for preparing the country for pandemics and other health emergencies Thursday, moving both nominations to the full Senate.
Dr. Erica Schwartz received support from every Republican present and Democratic Sen. Tim Kaine of Virginia to become CDC director. Sean Kaufman was backed by committee Republicans for assistant secretary for preparedness and response at the Department of Health and Human Services, while Democrats opposed him.
Their advancement begins to fill two positions that directly influence how hospitals, drugmakers, employers and state governments prepare for disease outbreaks and medical-supply emergencies.
Schwartz, a physician and former deputy U.S. surgeon general, would take control of a CDC that has faced leadership turnover, workforce departures and continuing disputes over vaccine policy. She would become the Trump administration’s third nominee for the position in less than two years.
During her confirmation hearing, senators pressed Schwartz on whether she would maintain scientific independence under Health Secretary Robert F. Kennedy Jr. She pledged transparency and said she would not betray scientific evidence, although some lawmakers remained dissatisfied with her reluctance to criticize individual administration decisions.
Kaine’s support gave the CDC nomination a measure of bipartisan backing. He had indicated that the agency needed a permanent leader as the country confronts multiple public-health threats.
Kaufman would oversee the Administration for Strategic Preparedness and Response, the HHS division responsible for coordinating the federal response to health emergencies and maintaining the Strategic National Stockpile.
That position carries substantial influence over federal purchases of vaccines, medications, protective equipment and emergency supplies. Decisions made by the office can determine which pharmaceutical manufacturers receive government contracts and how quickly hospitals obtain critical products during a crisis.
Kaufman faced sharper Democratic opposition over previous statements questioning vaccination policies and the government’s use of messenger RNA technology. At his hearing, he defended the technology’s potential while arguing that additional review was warranted.
Republicans framed both nominees as necessary leadership additions after prolonged vacancies across federal health agencies. Democrats focused on whether the appointees would challenge political pressure and protect established public-health practices.
Thursday’s votes were delayed from an earlier committee meeting after attendance problems prevented the panel from completing its work. The HELP Committee subsequently rescheduled both nominations for July 30.
Neither nominee has been confirmed. Both must still win approval from the full Senate, where Republicans hold the votes needed to confirm them unless significant opposition emerges within the party.
For businesses, the appointments could shape the government’s approach to workplace-health guidance, vaccine recommendations, emergency contracting and supply-chain planning. Hospitals and manufacturers will be watching particularly closely for changes to stockpile purchasing and future pandemic-preparedness programs.
JBizNews Desk | Washington
© JBizNews.com All Rights Reserved. Reproduction or distribution without written permission is prohibited.